Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580796 | 0.88 | IGF1R (0.53) | MAPTIGF1RALOX15LTA4HCALM1 | |
| SCHEMBL31294095 | 0.88 | AMY1A (0.68) | AMY1AMAPTIGF1RALOX15 | |
| SCHEMBL11097682 | 0.85 | CALM1 (0.51) | NPC1RAB9AIGF1RALOX15LTA4H | |
| SCHEMBL14283892 | 0.84 | LTA4H (0.53) | MAPTIGF1RALOX15LTA4HCALM1 | |
| SCHEMBL22500084 | 0.82 | AMY1A (0.61) | AMY1AL3MBTL1MAPTMAPK1IGF1R | |
| SCHEMBL2576239 | 0.82 | IGF1R (0.47) | NPC1MAPTRAB9AIGF1RALOX15 | |
| SCHEMBL11286798 | 0.81 | CNR2 (0.50) | L3MBTL1NPC1MAPTRAB9ALTA4H | |
| SCHEMBL4809365 | 0.81 | AMY1A (0.59) | AMY1AMAPTIGF1RALOX15SLC5A1 | |
| SCHEMBL15325999 | 0.80 | SLC5A2 (0.51) | LTA4HACHESLC5A1 | |
| SCHEMBL9657960 | 0.80 | LTA4H (0.46) | NPC1RAB9ALTA4HIDH1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| CN-101010276-B | Cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing same | CHUGAI PHARMACEUTICAL CO LTD | 2011-01-12 | — | — | CN | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| CN-101010276-A | Novel cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-08-01 | — | — | CN | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | AMY1A 74/4885L3MBTL1 1828/4885NPC1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.